Cargando…

Circulating tumor DNA for personalized lung cancer monitoring

Advances in deep sequencing technology have led to developments in personalized medicine. Here, we describe the implications of a recent investigation that sequenced ctDNA from the plasma of non-small cell lung cancer patients to develop personalized ctDNA tests. These ‘liquid biopsies’ have shown p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiala, Clare, Diamandis, Eleftherios P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559853/ https://www.ncbi.nlm.nih.gov/pubmed/28814291 http://dx.doi.org/10.1186/s12916-017-0921-6

Ejemplares similares

New approaches for detecting cancer with circulating cell-free DNA
por: Fiala, Clare, et al.
Publicado: (2019)

Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
por: Fiala, Clare, et al.
Publicado: (2018)

Can circulating tumor DNA be used for direct and early stage cancer detection?
por: Diamandis, Eleftherios P, et al.
Publicado: (2017)

Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm
por: Pons-Belda, Oscar D., et al.
Publicado: (2021)

The hundred person wellness project and Google’s baseline study: medical revolution or unnecessary and potentially harmful over-testing?
por: Diamandis, Eleftherios P
Publicado: (2015)

Make researchers revisit past publications to improve reproducibility
por: Fiala, Clare, et al.
Publicado: (2017)

The democratization of scientific publishing
por: Fiala, Clare, et al.
Publicado: (2019)

Mutations in normal tissues—some diagnostic and clinical implications
por: Fiala, Clare, et al.
Publicado: (2020)

The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
por: Diamandis, Eleftherios P
Publicado: (2012)

Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics?
por: Kulasingam, Vathany, et al.
Publicado: (2016)

My scientific genealogy and the Toronto ACDC Laboratory, 1988–2022
por: Diamandis, Eleftherios P.
Publicado: (2022)

DNA methylation signatures in circulating cell-free DNA for the monitoring of at-risk populations progressing to lung cancer
por: Tost, Jörg
Publicado: (2015)

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
por: Brenner Thomsen, Caroline, et al.
Publicado: (2022)

Fascin-1 is a novel biomarker of aggressiveness in some carcinomas
por: Kulasingam, Vathany, et al.
Publicado: (2013)

Towards personalized tumor markers
por: Kulasingam, Vathany, et al.
Publicado: (2017)

Multi Cancer Early Detection by Using Circulating Tumor DNA—The Galleri Test. Reply to Klein et al. The Promise of Multicancer Early Detection. Comment on “Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171”
por: Pons-Belda, Oscar D., et al.
Publicado: (2022)

Protect Your Fibroblasts Before They Become Gametes
por: Fernandez-Uriarte, Amaia, et al.
Publicado: (2022)

Circulating protein and antibody biomarker for personalized cancer immunotherapy
por: Yuan, Jianda
Publicado: (2016)

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
por: ALEMZADEH, EFFAT, et al.
Publicado: (2023)

Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer
por: Kim, Young-Woo, et al.
Publicado: (2019)

The struggle to detect circulating DNA
por: Zeerleder, Sacha
Publicado: (2006)

Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.
por: Sauter, Edward R, et al.
Publicado: (2002)

Circulating Tumor DNA: A Potential Novel Diagnostic Approach in Gestational Trophoblastic Neoplasia
por: Bolze, Pierre-Adrien, et al.
Publicado: (2016)

Cerebrospinal fluid: A unique source of circulating tumor DNA with broad clinical applications
por: Hickman, Richard A., et al.
Publicado: (2023)

Consumer-grade electroencephalography devices as potential tools for early detection of brain tumors
por: Samuel, Nardin, et al.
Publicado: (2021)

Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Lung Cancer Early Detection: The Role of Circulating MicroRNAs
por: Bianchi, Fabrizio
Publicado: (2015)

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023)

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
por: Cheng, Lei, et al.
Publicado: (2023)

Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response
por: Li, Rui-Yu, et al.
Publicado: (2020)

Towards identification of true cancer biomarkers
por: Diamandis, Eleftherios P
Publicado: (2014)

Recent translational research: circulating tumor cells in breast cancer patients
por: Müller, Volkmar, et al.
Publicado: (2006)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2021)

Arterial or Venous: Where Are the Circulating Tumor Cells?
por: Gray, Elin S.
Publicado: (2015)

Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
por: Wehrle, Julius, et al.
Publicado: (2020)

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials
por: Nawaf, Cayce, et al.
Publicado: (2023)

The sweet and sour of serological glycoprotein tumor biomarker quantification
por: Kuzmanov, Uros, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_csm909d53jcrfivuu5il0cbqs6